Lee Troy Schalop
Known title: DirectorCIK: 0002072339
Lee Troy Schalop's purchase track record
Lee Troy Schalop has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/12/2026 | LTRN | $100K | +37.9% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LTRN | ▲ Buy | Open Market | 48,544 | $100K | 5/12/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Lantern Pharma Announces $8M Direct Offering and AI Roadmap
Lantern Pharma said it will raise up to $8 million through a registered direct offering. The company also outlined its Open‑Medicine AI platform roadmap, highlighting plans to use agentic AI for drug development. It presented these ideas on Bloomberg Television and in a SeekingAlpha slideshow. The move could support future product pipelines, while the stock’s low RSI and recent volume spike suggest increased investor interest.
Lantern Pharma Announces $8M Direct Offering and AI Roadmap. Lantern Pharma said it will raise up to $8 million through a registered direct offering. The company also outlined its Open‑Medicine AI platform roadmap, highlighting plans to use agentic AI for drug development. It presented these ideas on Bloomberg Television and in a SeekingAlpha slideshow. The move could support future product pipelines, while the stock’s low RSI and recent volume spike suggest increased investor interest.